Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06470295
EARLY_PHASE1

Effect of C-peptide on Hypoglycemic Counterregulation

Sponsor: University of Cincinnati

View on ClinicalTrials.gov

Summary

Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.

Official title: On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia

Key Details

Gender

All

Age Range

18 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

38

Start Date

2024-06-01

Completion Date

2028-01-01

Last Updated

2026-02-17

Healthy Volunteers

Yes

Interventions

OTHER

Saline

Normal saline will be infused during insulin-induced hypoglycemia

BIOLOGICAL

C-peptide

C-peptide will be infused during insulin-induced hypoglycemia

Locations (1)

University of Cincinnati

Cincinnati, Ohio, United States